Introduction: Acquired resistance to anti-hormonal agents in breast cancer is frequently associated with altered growth factor expression and the development of an aggressive cell phenotype in vitro. Chronic exposure of MCF-7 cells to the pure antioestrogen Fulvestrant results in acquired Fulvestrant resistance. Significantly, these resistant cells also overexpress the c-Met receptor, a protein that clinically has been linked to invasive breast carcinoma and metastasis. Subsequent exposure of Fulvestrant-resistant (Fas-R) cells to the c-Met ligand, hepatocyte growth factor/scatter factor (HGF/SF), results in a profound increase in their motile and invasive capacities. In other cancer cells, HGF/SF is known to induce invasive behavio...
MET and its ligand HGF are involved in many biological processes, both physiological and pathologica...
The development of multidrug resistance greatly impedes effective cancer therapy. Recent advances in...
ABSTRACT Targeted therapies have opened new perspectives in clinical oncology. However, clinicians h...
Introduction: Acquired resistance to anti-hormonal agents in breast cancer is frequently associated...
The pure anti-oestrogen faslodex presents a valuable therapeutic option for post-menopausal women wi...
Hepatocyte growth factor/scatter factor (HGF/SF), a cytokine associated with cancer cell migration a...
The hepatocyte growth factor (HGF) receptor, Met, is frequently overexpressed in nasopharyngeal canc...
<div><p>The chemokine receptor CXCR4 and its ligand CXCL12 have been shown to mediate the metastasis...
AbstractThe hepatocyte growth factor (HGF) receptor, Met, is frequently overexpressed in nasopharyng...
The chemokine receptor CXCR4 and its ligand CXCL12 have been shown to mediate the metastasis of many...
<p>JJ012 cells were incubated with HGF for 24 h (A) or pretreated with c-Met inhibitor, Ly294002, wo...
The Hepatocyte growth factor (HGF)—mesenchymal-epithelial transition (MET) pathway is deregulated in...
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused ...
The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed a...
The Hepatocyte growth factor (HGF)-mesenchymal-epithelial transition (MET) pathway is deregulated in...
MET and its ligand HGF are involved in many biological processes, both physiological and pathologica...
The development of multidrug resistance greatly impedes effective cancer therapy. Recent advances in...
ABSTRACT Targeted therapies have opened new perspectives in clinical oncology. However, clinicians h...
Introduction: Acquired resistance to anti-hormonal agents in breast cancer is frequently associated...
The pure anti-oestrogen faslodex presents a valuable therapeutic option for post-menopausal women wi...
Hepatocyte growth factor/scatter factor (HGF/SF), a cytokine associated with cancer cell migration a...
The hepatocyte growth factor (HGF) receptor, Met, is frequently overexpressed in nasopharyngeal canc...
<div><p>The chemokine receptor CXCR4 and its ligand CXCL12 have been shown to mediate the metastasis...
AbstractThe hepatocyte growth factor (HGF) receptor, Met, is frequently overexpressed in nasopharyng...
The chemokine receptor CXCR4 and its ligand CXCL12 have been shown to mediate the metastasis of many...
<p>JJ012 cells were incubated with HGF for 24 h (A) or pretreated with c-Met inhibitor, Ly294002, wo...
The Hepatocyte growth factor (HGF)—mesenchymal-epithelial transition (MET) pathway is deregulated in...
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused ...
The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed a...
The Hepatocyte growth factor (HGF)-mesenchymal-epithelial transition (MET) pathway is deregulated in...
MET and its ligand HGF are involved in many biological processes, both physiological and pathologica...
The development of multidrug resistance greatly impedes effective cancer therapy. Recent advances in...
ABSTRACT Targeted therapies have opened new perspectives in clinical oncology. However, clinicians h...